N-(2,2-二甲氧基乙基)甲酰胺 | 135393-73-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2,2-二甲氧基乙基)甲酰胺
• 英文名称: (N-formylamino)acetaldehyde dimethyl acetal
• 英文别名: N-(2,2-dimethoxyethyl)formamide
• CAS: 135393-73-6
• 化学式: C₅H₁₁NO₃
• 分子量: 133.147
• InChiKey: HHRBHXDVRRCGQY-UHFFFAOYSA-N

物化性质

• 沸点：
  263℃
• 密度：
  1.021
• 闪点：
  113℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2,2-二甲氧基乙基)甲酰胺 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以57%的产率得到1,1-二甲氧基-2-异氰酰基乙烷
  参考文献：
  名称：

  A straightforward approach towards thiazoles and endothiopeptides via Ugi reaction

  摘要：

  使用硫代酸作为酸组分，通过 Ugi 反应可以很容易地获得内硫肽。如果使用带有缩醛基团的异腈，则内硫肽可在微波辐照下使用 TMSCl-NaI 直接转化为噻唑。

  DOI：

  10.1039/b507028g
• 作为产物：
  描述：

  甲酸丙酯 、 氨基乙醛缩二甲醇 反应 3.0h， 生成 N-(2,2-二甲氧基乙基)甲酰胺
  参考文献：
  名称：

  2,2-DIETHOXY-1-ISOCYANOETHANE

  摘要：

  DOI：

  10.15227/orgsyn.082.0018

文献信息

• Iodospirocyclization of Tryptamine‐Derived Isocyanides: Formal Total Synthesis of Aspidofractinine
  作者：Jordy M. Saya、Thomas R. Roose、Jarryt J. Peek、Bram Weijers、Thomas J. S. de Waal、Christophe M. L. Vande Velde、Romano V. A. Orru、Eelco Ruijter

  DOI：10.1002/anie.201809678

  日期：2018.11.12

  N‐iodosuccinimide‐mediated spirocyclization of tryptamine‐derived isocyanides to generate spiroindolenines is reported. The products contain both an imine and an imidoyl iodide as flexible handles for follow‐up chemistry. Nucleophilic addition typically occurs chemoselectively on the imine moiety with complete diastereoselectivity, providing opportunities for the construction of complex molecular frameworks

  据报道，N-碘丁二酰亚胺介导的色胺的异氰酸酯的螺环化反应可生成螺吲哚烯。该产品同时包含亚胺和亚氨基碘化物，可作为后续化学反应的灵活处理方法。亲核加成通常在亚胺部分上以化学选择性发生，具有完全的非对映选择性，为构建复杂的分子框架提供了机会。该方法的合成潜力在（±）-aspidofractinine的正式总合成中得到了证明。
• Formyloxyacetoxyphenylmethane as an <i>N</i>-Formylating Reagent for Amines, Amino Acids, and Peptides
  作者：Robert S. L. Chapman、Ruth Lawrence、Jonathan M. J. Williams、Steven D. Bull

  DOI：10.1021/acs.orglett.7b02382

  日期：2017.9.15

  Formyloxyacetoxyphenylmethane is a stable, water-tolerant, N-formylating reagent for primary and secondary amines that can be used under solvent-free conditions at room temperature to prepare a range of N-formamides, N-formylanilines, N-formyl-α-amino acids, N-formylpeptides, and an isocyanide.

  Formyloxyacetoxyphenylmethane是一种稳定的，水耐受性，Ñ对于可以无溶剂的条件下在室温下可用于制备一系列的伯和仲胺-formylating试剂Ñ -formamides，Ñ -formylanilines，Ñ甲酰基α氨基酸，N-甲酰基肽和异氰化物。
• [EN] 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS<br/>[FR] 3-PIPERIDINYLISOCHROMAN-5-OLS UTILISES EN TANT QU'AGONISTES DE LA DOPAMINE
  申请人：AVENTIS PHARMA INC

  公开号：WO2005111025A1

  公开（公告）日：2005-11-24

  The present invention provides compounds of formula (I): a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula (I).

  本发明提供了式(I)的化合物：其立体异构体或药学上可接受的盐，其中变量R1、R2、R3、R4、X和n如此处所定义。另外，提供了一种用于治疗多巴胺相关神经系统疾病的方法，所述疾病包括神经系统、心理、心血管、认知或注意力障碍、物质滥用和成瘾行为，或其组合，包括向需要此类治疗的患者施用式(I)的化合物的治疗有效量。
• Dopaminergic compounds
  申请人：Abbott Laboratories

  公开号：US04994486A1

  公开（公告）日：1991-02-19

  Novel compounds of Formula (I): ##STR1## or pharmaceutically acceptable salts, esters and amides thereof, wherein A is O, C, CH or CH.sub.2, n is 0 or 1, and the dotted line is a single bond when A is O or CH.sub.2 and a double bond when A is CH or when n=0, A is C and R.sub.6 and A taken together form a nitrogen-containing heterocycle; R is hydrogen, lower alkyl or a readily cleavable group; R.sub.1 is selected from hydrogen, halogen, lower alkyl, haloalkyl and lower alkoxy; R.sub.2 is selected from hydrogen, halogen, lower alkyl and haloalkyl or, taken together with R.sub.8, forms a fused ring; R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or arylalkyl or, taken together with R.sub.4, forms a spirocycloalkyl or, taken together with R.sub.5, forms a fused cycloalkyl; R.sub.4 is hydrogen or alkyl or, taken together with R.sub.3, forms a spirocycloalkyl; R.sub.5 is hydrogen or alkyl or, taken together with R.sub.3, forms a fused cycloalkyl; R.sub.6 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or arylalkyl or, taken together with A when A is C and when n is 0, forms a fused nitrogen-containing heterocycle or, taken together with R.sub.7 or R.sub.8, forms a nitrogen-containing heterocycle; R.sub.7 is hydrogen or alkyl or, taken together with R.sub.6 or R.sub.8, forms a nitrogen-containing heterocycle; R.sub.8 is hydrogen or alkyl or, taken together with R.sub.6 or R.sub.7, forms a nitrogen-containing heterocycle or, taken together with R.sub.2, forms a fused ring, with the proviso that R.sub.3 and R.sub.4 cannot simultaneously both be hydrogen, are selective dopaminergic agents and are useful for treating disorders characterized by abnormal dopaminergic activity in the central or the peripheral nervous system, for example, neurological disorders such as psychoses, Parkinson's Disease, certain cardiovascular disorders and addictive behavior disorders.

  化合物的化学式（I）的新颖化合物：##STR1##或其药学上可接受的盐、酯和酰胺，其中A为O、C、CH或CH.sub.2，n为0或1，虚线是当A为O或CH.sub.2时为单键，当A为CH或n=0时为双键，当A为C且R.sub.6和A一起形成含氮杂环时，R为氢、低碳烷基或易解离基团；R.sub.1选择自氢、卤素、低碳烷基、卤代烷基和低烷氧基；R.sub.2选择自氢、卤素、低碳烷基和卤代烷基或与R.sub.8一起形成融合环；R.sub.3为氢、烷基、烯基、炔基、环烷基、芳基或芳基烷基或与R.sub.4一起形成螺环烷基或与R.sub.5一起形成融合环烷基；R.sub.4为氢或烷基或与R.sub.3一起形成螺环烷基；R.sub.5为氢或烷基或与R.sub.3一起形成融合环烷基；R.sub.6为氢、烷基、烯基、炔基、环烷基或芳基烷基或与A一起形成融合含氮杂环或与R.sub.7或R.sub.8一起形成含氮杂环；R.sub.7为氢或烷基或与R.sub.6或R.sub.8一起形成含氮杂环；R.sub.8为氢或烷基或与R.sub.6或R.sub.7一起形成含氮杂环或与R.sub.2一起形成融合环，但R.sub.3和R.sub.4不能同时都是氢，是选择性多巴胺能作用剂，用于治疗中枢或外周神经系统中存在异常多巴胺能活性的疾病，例如，神经症、帕金森病、某些心血管疾病和成瘾行为障碍。
• Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands
  作者：Michael R. Michaelides、Robert Schoenleber、Sheela Thomas、Diane M. Yamamoto、Donald R. Britton、Robert MacKenzie、John W. Kebabian

  DOI：10.1021/jm00114a002

  日期：1991.10

  A series of 3-substituted 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2- benzopyrans were prepared as potential D1 selective antagonists. The compounds were evaluated for their affinity and selectivity for the D1 receptor as well as for their functional antagonism of D1-mediated pharmacological events. The compounds show potent D1 antagonist properties in vitro. The optimum nitrogen substitution was found

  制备了一系列3-取代的1-（氨基甲基）-3，4-二氢-5-羟基-1H-2-苯并吡喃，作为潜在的D1选择性拮抗剂。评价化合物对D1受体的亲和力和选择性，以及对D1介导的药理作用的功能拮抗作用。这些化合物在体外显示出有效的D1拮抗剂特性。发现最佳的氮取代是伯胺，并且观察到的在6-位取代的效力的顺序是OH大于Br大于H大于OMe。还对体内的两种代表性化合物（6-甲基和6-溴类似物）的多巴胺能活性进行了评估。有趣的是，两种化合物均表现为有效的体内激动剂。